sees fy gaap earnings per share growth of 10-15%.
board provides full year outlook, and also announces quarterly dividend.
compname reports q3 adjusted earnings per share of $1.43.
q4 adjusted earnings per share $1.05.
anticipates full-year 2022 outlook to be challenged on a cash basis.
qtrly consolidated results of fy sales of $4.7 billion.
qtrly q2 earnings per share $0.89.
q4 hepcat revenue declined about 20%.
qtrly adjusted gross profit in q3 of 2021 decreased 1% to $1.1 billion.
continues its robust operating performance in other segment of animal health, as well as global commercialization, animal health.
expresses q2 2021 revenue growth in a significant way.
compname reports quarterly operating results.
compname reports full year 2021 results for comparable period.
compname announces third quarter 2021 results.
compname says it had no meaningful impact on co's business due to continued supply chain challenges.
q3 operating expenses increased 6 percent compared to q3 2021.
